Velicept lines up for $21M; Scientists unveil improved gene editing tool;

@FierceBiotech: Real R&D innovation demands that lines between academia and industry are blurred. Article | Follow @FierceBiotech

@JohnCFierce: Disgraced scientist's China venture resurrects fears of a human cloning comeback. Story | Follow @JohnCFierce

@DamianFierce: Actually, inversions are ... good? More from the NYT | Follow @DamianFierce

> Velicept Therapeutics closed the first tranche of a $21 million B round, earmarking the funds for a Phase II study of solabegron, an in-development treatment for overactive bladder. More

> Researchers have developed a revamped CRISPR technology they say can edit genetic code with fewer errors than previous methods. Story

> New York's Remedy Pharmaceuticals raised $9 million to support its development of an intravenous treatment for stroke. News

Medical Device News

@FierceMedDev: From FierceDrugDelivery: Adapt Pharma earns FDA approval of first intranasal spray for emergency opioid overdose. Article | Follow @FierceMedDev

@VarunSaxena2: AstraZeneca begins dosing in trial of its Bind-partnered cancer candidate. More from FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: A behind-the-scenes look at Cards Against Biotechnology, Cubist's snarky 'last hurrah': FiercePharmaMarketing item | Follow @EmilyWFierce

> Nevro scores a victory in spinal cord stimulation patent battle with Boston Scientific. Article

> Q&A: Philips on what's next after the first year of HealthTech. Report

Pharma News

@FiercePharma: Japan reaping the benefits from faster approval process. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce:  last week: FDA warning letter says Dr Reddy's hid existence of QC testing lab where retesting was done. Report | Follow @EricPFierce

@CarlyHFierce:  last week: Trump, Clinton lash out at Pfizer over Allergan deal agreement. Article | Follow @CarlyHFierce

> Russia amps up spending on locally made meds to spur Big Pharma production. Item

> Allergan investors still too 'skeptical' about a Pfizer merger, analyst says. Report

> Express Scripts backs Imprimis' $1-per-pill rival to Turing's pricey Daraprim. Article

Pharma Manufacturing News

> Xellia buys idled Bedford plant from Hikma, will hire 170. Report

> FDA warning letter blasts Dr. Reddy's for undisclosed testing. News

> Samsung BioLogics to build its third and largest plant in South Korea. Story

> Meda sells off Spain operation that makes Legalon API. Article

> GE investing $40M in Ireland plant and will add 140 jobs. Item

Pharma Asia News

> Pharmaceuticals in South Korea could drive economy's growth. Item

> Survey: Rates of HIV in Asia could reflect 'hidden epidemic.' More

> Israel's Teva and Takeda tie up for Japan generics business. Report

> Delhi court rules for Dr. Reddy's in Xarelto case. Story

> Russia hopes to lure drugmakers with increase in buying power. Article

Drug Delivery News

> Nature: Electronic on-demand delivery device is also bioresorbable. More

> Indian Institute of Science develops hep C delivery vehicle using siRNA. Story

> UCSD develops tech to isolate drug-delivery nanoparticles from the blood. Item

> Presage licenses cancer drug from India's Piramal to accelerate development using its microinjector. Report

> Impax earns permission to sell its FDA-approved modified-release Parkinson's med in Europe. Article

Suggested Articles

Medimmune’s Ronald Herbst, Ph.D., has followed a series of other AstraZeneca and its biologics arm staffers out the door.

The takeover will give Alexion two clinical-phase medicines in development in complement alternative pathway-mediated rare diseases.

Last year, Eli Lilly spent $1.6 billion to get its hands on Armo Biosciences and its lead asset, pegilodecakin. Today, that drug flopped.